Synonyms: BBI-503 | BBI503
Compound class:
Synthetic organic
Comment: Amcasertib (BBI503) is a first-in-class, orally active, cancer stemness kinase inhibitor has been developed by Boston Biomedical for potential anticancer activity [1]. by targeting certain kinase enzymes it is reported to inhibit Nanog (NANOG; Q9H9S0) and other signalling pathways that control stem-cell replication, survival and differentiation. To date (April 2018) the only reports of BBI503 mechanism of action and clinical efficacy are in the form of meeting abstracts, and not in peer reviewed articles. Amcasertib is one of the chemical structures claimed in patent US8299106B2 [2], which were discussed as potential PDGFRα inhibitors therein.
|
|
References |
1. Ajani JA, Song S, Hochster HS, Steinberg IB. (2015)
Cancer stem cells: the promise and the potential. Semin Oncol, 42 Suppl 1: S3-17. [PMID:25839664] |
2. Li CJ, Liu J-F, Li Y, Li W, Rogoff H. (2012)
Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases. Patent number: US8299106B2. Assignee: Boston Biomedical Inc. Priority date: 06/09/2007. Publication date: 30/10/2012. |